Navigation Links
University of Colorado Cancer Center Review Shows Long-term Side-effects of New, Targeted Therapies in Pediatric Cancer Patients
Date:2/7/2013

Aurora, COLO (PRWEB) February 07, 2013

A University of Colorado Cancer Center review published this week in the journal Lancet Oncology describes possible long-term side-effects of new, targeted therapies in pediatric cancer patients: what we don’t know may hurt us.

“As pediatricians who treat kids with cancer, we expect the side-effects of traditional chemotherapies: low white blood count, infections, even long-term heart trouble or infertility. But there’s the impression that these new, molecularly targeted agents are much less toxic. That may be true, especially in adult patients, but until we have more information about the long-term effects of these therapies in children, we need to be careful about how and when we prescribe them,” says Chris Porter, MD, CU Cancer Center investigator and assistant professor of Pediatrics at the University of Colorado School of Medicine.

Already we know that molecularly targeted therapies may stunt the growth of pediatric patients, delay puberty or speed the onset of diabetes. And researchers are just now starting to ask about additional, sometimes unforeseen side-effects, potentially including more subtle issues such as neurocognitive, balance and motor defects.

“The growth of cancer cells isn’t that different than the growth of a 7-pound baby into a 210-pound teenage linebacker. Now, you shut down these growth pathways in an adult and it might not be a big deal, but you shut down these same pathways at a critical time in childhood development and you can have real problems,” says Lia Gore, MD, CU Cancer Center investigator and associate professor of Pediatrics and Medical Oncology at the CU School of Medicine.

The practical problem is this: FDA approval of many of these drugs for adult use allows physicians to prescribe the same drugs for pediatric use. Many are pills – orally administered, outpatient treatments that make it difficult to recognize and track possible side-effects even in the short-term, let alone 10, 15 or 60 years later.

“The message I really want to convey is that our way of treating pediatric cancer has changed entirely in some diseases, and in some it’s meant huge progress. A number of us have patients who have literally been cured by these new drugs. There are a lot of really cool therapies out there, but the issue is using them safely. With increased survival, we need to cure kids for 60-70 years. The question is how do we best treat these kids, knowing that cancer remains the enemy but you also don’t want to induce complications that negatively affect the rest of their lives,” Gore says.

“Personally, one of the most important things when choosing how to treat pediatric patients is to know what I don’t know – to acknowledge gaps in knowledge. Then as a researcher, we try to fill these gaps so that we can prescribe knowing the balance of risk and reward for these treatments,” Porter says.

For now and until these questions are answered, the researchers recommend using molecularly targeted therapies with pediatric patients only in the context of a clinical trial. To Gore, Porter and co-author James DeGregori, PhD, the framework of a clinical trial provides the oversight needed for the rational prescription of these drugs in pediatric patients – along with follow-up that includes more definite monitoring of side-effects than what Gore describes as “random use.”

“One of the reasons we wrote this paper is that we don’t understand the major risks, or even what the major risks might be,” Porter says. “These targeted agents may affect the process of development in ways we can’t predict.”

Read the full story at http://www.prweb.com/releases/2013/2/prweb10409854.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Elsevier and Kanazawa University in Japan Collaborate to Map Universitys Research Performance
2. Two University of Colorado Cancer Center Studies Show that Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
3. WaferGens MyDesign Open Platform Facilitates Rapid Development of a Proprietary Prostate Cancer Diagnostic Panel in the Lab of Dr. Arul Chinnaiyan at the University of Michigan Cancer Center
4. NextBio Teams With Emory University and the Aflac Cancer Center to Improve Outcomes for Children with Medulloblastoma
5. Notre Dame to be part of $194 million university research center network
6. University of Minnesota awarded $28 million grant to lead microelectronics development
7. Krishagni Enables University of New South Wales (Australia) to Adopt caTissue Plus
8. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
9. Rice University discovers that graphene oxide soaks up radioactive waste
10. Carin Grings remains identified by researchers at Uppsala University
11. Nanonex Delivered Advanced Nanoimprint Tool NX-B200 to Swinburne University of Technology, Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Ltd. ("Sinovac" or the "Company") (NASDAQ: SVA), a leading provider of ... its board of directors has amended its shareholder rights plan. The amendment ... to March 27, 2018. The amendment was not in response to any ... ... is a China -based biopharmaceutical company that focuses ...
(Date:3/23/2017)... ... , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking event company ... around the world, such as Illumina, HP and Qualcomm, and is ranked #1 in its ... is due to its new team building format, a way for teams to not only ...
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
Breaking Biology Technology:
(Date:3/20/2017)... -- At this year,s CeBIT Chancellor Dr. Angela Merkel ... Chancellor came to the DERMALOG stand together with the Japanese Prime Minster ... country. At the largest German biometrics company the two government leaders could ... recognition as well as DERMALOG´s multi-biometrics system.   ... ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... March 7, 2017 Brandwatch , the leading social ... The Prince,s Trust to uncover insights to support its reporting, ... The UK,s leading youth charity will be using Brandwatch ... and get a better understanding of the topics and issues that ... ...
Breaking Biology News(10 mins):